<![CDATA[VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors]]>

Phase 2positiveVS-7375Positive

AI Analysis

Summary

The oral KRAS G12D inhibitor VS-7375 demonstrated clinical responses in patients with pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.

Clinical Trial Data

Phase

1/2

Outcome Details

Produced responses in pancreatic, colorectal, and lung cancers

Importance:6/10

Sentiment:

0.70

KRAS G12D inhibitororalpancreatic cancercolorectal cancerlung cancerTARGET-D 101 trial

Related Companies

$INTI $CBDY $SLDB

Read the original article

Published by Cancer Network on October 14, 2026 2:30 PM

Read Original